Frontlight ResearchEarly access
Taking people in NetherlandsPhase 1
Study of how brensocatib and midazolam affect each other in the body
Tests how brensocatib and midazolam interact in adults with non-cystic fibrosis bronchiectasis.
Key facts
- Who runs it
- Insmed Inc.
- Where
- Groningen, NetherlandsSee the site
- Trial code
- Registry title
- Drug-drug interaction study of midazolam and brensocatib
- Status
- Recruiting
- Phase
- Phase 1
- People taking part
- 26 people, planned
- Started
- 6 Oct 2026
- Planned end
- 5 Nov 2026
- Type of study
- Interventional
- Record updated
- 10 November 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 18 to 64 to study how midazolam and brensocatib act together. The condition listed is non-cystic fibrosis bronchiectasis.
- Age
- 18 to 64 years
- Sex
- All sexes can join.
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 64 years old?
Where in Netherlands
- Pharmaceutical Research Associates Group B.V.Groningen, NetherlandsTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).
- Plain-language title
- Study of how brensocatib and midazolam affect each other in the bodyGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 11 November 2026.
- Fit questions
- Built from 2026-526670-16-00, who can take part
- Record updated
- 10 November 2026